Views

Illuminating the IRA: Key Questions from the First Round of MFP Negotiations
Delve into our comprehensive review of CMS's first round of maximum fair price negotiations under the Inflation Reduction Act. Uncover the answers to three critical questions about patient perspectives, therapeutic alternatives, and generic inclusion that could reshape the future of medication pricing.
View Jan 21, 2025
Drill Down & Catch Up: The Role of Biomarkers in Neurodegenerative Disease
Lumanity offers extensive experience-based strategic guidance and insights in the field of neuroscience. Our goal is to provide our clients with actionable solutions that de-risk and optimize the development and commercialization of therapies, ultimately improving the lives of patients who are impacted across a range of conditions.
View Nov 4, 2024